Exploring the clinical usefulness of the low-FODMAP diet for Crohn’s disease
Tuesday, 18 October 2016 11:26
A diet low in FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) has been studied mostly in the context of irritable bowel syndrome (IBS) and is known to reduce functional gastrointestinal symptoms in this population. In addition, altering FODMAP intake appears to impact fecal microbiota composition in both healthy individuals and those with IBS.
The observed success of the low-FODMAP diet in reducing gastrointestinal (GI) symptoms in IBS made a group of researchers ask whether the diet could also address functional GI symptoms in those with inflammatory bowel diseases (IBDs) such as Crohn’s disease. This idea was explored in a recent study from the group at Monash University (Australia) that originally developed and tested the low-FODMAP diet.
In this cross-over trial, researchers first tracked the habitual diets of a small group of nine patients with inactive Crohn’s disease. Next, each participant was randomized to 21 days of a provided experimental diet: either (1) low-FODMAP or (2) typical “Australian”. After a washout period of his or her habitual diet for at least 21 days (until GI symptoms had returned to baseline), each participant consumed the other experimental diet for an additional 21 days.
Dietary fibre/short-chain fatty acids and vitamin A may protect mice against peanut allergy via gut microbiota
Tuesday, 18 October 2016 11:18
The incidence of food allergies has increased dramatically in western countries over the past 20 years and the gut microbiota seems to be a promising target for preventing and treating them. However, mechanisms by which gut microbiota is involved in the loss of oral tolerance remain unclear.
A recent study, led by Dr. Charles Mackay from the Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology at Monash University in Clayton (Australia), has found that the development of food allergies in mice could be linked to dietary elements including fibre and vitamin A.
Probiotics could help combat small intestinal bacterial overgrowth in patients with gastrointestinal cancer
Tuesday, 18 October 2016 11:10
Small intestinal bacterial overgrowth (SIBO) refers to a condition in which abnormally large numbers of bacteria are present in the small intestine. Gastrointestinal cancer is related to compromised intestinal barrier function, reduced functionality of immune responses, and inadequate nutritional status, which impair the ability of patients to control intestinal bacterial proliferation. These result in conditions favourable to SIBO. However, the actual incidence of SIBO in patients with gastrointestinal cancer and its relation to clinical symptoms has not been explored.
A recent case-control study, led by Dr. Zhenjun Wu from the Department of Blood Transfusion and Clinical Laboratory at Qingdao University School of Medicine in Qingdao (China), has found that probiotics may combat SIBO in patients with gastrointestinal cancer and may alleviate some gastrointestinal symptoms.Further Information
- Gut bacteria alterations impact serum metabolites and may contribute to insulin resistance
- Microbiome disruptions could explain HIV-exposed babies’ increased risk of morbidity and mortality
- An interview with Bernd Schnabl: “Chronic alcohol alters gut microbiota and can lead to bacterial overgrowth”
- Report from Mucosal Immunology Course and Symposium in Toronto, Canada
Page 1 of 28